

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION		
10/029,322	12/20/2001	David William Koenig	KCC 4788 (K.C. No. 15,397	6145	
	590 08/05/2004		EXAMINER		
SENNIGER POWERS LEAVITT AND ROEDEL ONE METROPOLITAN SQUARE 16TH FLOOR			COLE, ELIZ	COLE, ELIZABETH M	
			ART UNIT	PAPER NUMBER	
ST LOUIS, M	O 63102		1771	-	

DATE MAILED: 08/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
Office Action Summary		10/029,322	KOENIG ET AL.	
		Examiner	Art Unit	
		Elizabeth M. Cole	1771	
Period fo	The MAILING DATE of this communication app r Reply	pears on the cover sheet with th	e correspondence address	
THE N - Exten after: - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.1: SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period version to reply within the set or extended period for reply will, by statute apply received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS from the application to become ABANDO	e timely filed days will be considered timely. om the mailing date of this communication.	
1)	Responsive to communication(s) filed on 16 F	Sobruany 2004		
2a)⊠		This action is non-final.		
3)	Since this application is in condition for allowa		managed to the state of the sta	
,—	closed in accordance with the practice under a condition of claims	Ex parte Quayle, 1935 C.D. 11	, 453 O.G. 213.	
4)🖂	Claim(s) <u>1-6,9-17,20-23,26-28,31-35 and 38</u> is	s/are pending in the application	l.	
4	la) Of the above claim(s) is/are withdrav	vn from consideration.		
5)	Claim(s) is/are allowed.			
6)🖂	Claim(s) <u>1-6, 9-17, 20-23, 26-28, 31-35, 38</u> is/a	are rejected.		
7)	Claim(s) is/are objected to.			
8) 🗌	Claim(s) are subject to restriction and/or	election requirement.		
Application	on Papers	·		
9)□ T	he specification is objected to by the Examiner	·.		
10)∐ T	he drawing(s) filed on is/are: a)□ accep	ted or b) objected to by the Ex	caminer.	
7 l <u> </u>	Applicant may not request that any objection to the	· ·	• •	
11)[T	he proposed drawing correction filed on		roved by the Examiner.	
	If approved, corrected drawings are required in rep	-		
	he oath or declaration is objected to by the Exa	aminer.		
	nder 35 U.S.C. §§ 119 and 120			
	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119	(a)-(d) or (f).	
a)[All b)☐ Some * c)☐ None of:			
1	Certified copies of the priority documents	have been received.		
2	2. Certified copies of the priority documents have been received in Application No			
	B. ☐ Copies of the certified copies of the priori application from the International Bur ee the attached detailed Office action for a list o	eau (PCT Rule 17.2(a)).	•	
	knowledgment is made of a claim for domestic			
a)	The translation of the foreign language proveknowledgment is made of a claim for domestic	visional application has been re	eceived.	
\ttachment(7	TO SHIM OF TET.	
) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) tion Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ary (PTO-413) Paper No(s). <u>クンす</u> る. Il Patent Application (PTO-152)	
Patent and Trac O-326 (Rev.	emark Office	ion Summary	Part of Paper No. 0728	

Art Unit: 1771

- 1. Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.
- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 1-7, 9-11, 14-17, 20-23, 26-28, 31-35, 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mandell et al in view of Romano, WO 97/31092. Mandell discloses an absorbent product comprising an osmoregulation protector such as a betaine. See page 16, lines12- page 17, line 33. The osmoregulation protector may be incorporated into a shell material such as a superabsorbent particle. See page 28. The betaine acts to prevent the formation of ammonia formation. See page 3, lines 6-9.
- 4. Mandell differs from the claimed invention because Mandell does not disclose the claimed amounts of osmoregulation protector employed in terms of milligrams per grams of product. However, Mandell teaches employing an effective amount. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected the amount to employ through the process of routine experimentation. Mandell also differs from the claimed invention because Mandell does not specifically disclose glycine betaine. Romano teaches employing glycine betaine in an amount which is effective to interact with bacteria in a wet wipe. See page 7, line 13 page 8, line 28.

Application/Control Number: 10/029,322

Art Unit: 1771

- 5. Claims 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mandell in view of Romano, as applied to claims above, and further in view of Lorenzi et al, U.S. Patent No. 6,217,889. Lorenzi teaches that liposomes maybe incorporated into personal absorbent articles and cleansing wipes along with betaines in order to enhance the skin soothing properties of the absorbent articles and cleansing wipes. See col. 15, lines 1-21 and col. 2412-15. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have further incorporated liposomes into the material of Mandell as taught by Lorenzi, motivated by the expectation that this would further enhance the skin soothing properties of the articles.
- 6. Applicant's arguments filed 2/16/04 have been fully considered but they are not persuasive.
- 7. Applicant's discussion of the Mandell reference and the requirements for a showing of obviousness as set forth in MPEP 2143 at pages 3 through the first full paragraph of paragraph 4 have been considered.

Applicant argues that Romano et al requires that the sum of R1, R2 and R3 in the formula set forth at page 8 of Romano et al be 14-24 carbon atoms and that therefore Romano cannot teach glycine betaine because in glycine betaine the sum of the carbon atoms R1, R2 and R3 equals 3. Applicant argues that this position is supported because every specific betaine compound disclosed by Romano et al meets the requirement of having R1 + R2 + R3 equal 14-24. However, Romano teaches at page 8, line 18 that C10 alkyl dimethyl betaine is an example of a useful betaine. The sum of R1 + R2 + R3 for this compound is 12 which is outside the range of 14-24, but Romano teaches that it is a suitable betaine. Therefore, it is the examiner's position that Romano does not require the sum of R1 + R2 + R3 to be within 14 -24, since exemplified

Application/Control Number: 10/029,322

Art Unit: 1771

compounds in Romano are outside the range. Further, looking at the preferred ranges of Romano, in situations where R1 is 8-11 which is a preferred range for R1 and R2 and R3 are 1 which is the preferred value for R2 and R3, the sum would also be outside of the range of 14-24. Applicant argues that construing the "wherein" clause of Romano as a requirement rather than a preferred embodiment is consistent with the only specific betaine compounds listed by Romano et al. However, as set forth above, C10 alkyl dimethyl betaine is listed as a suitable betaine compound and it would not meet the sum of R1 + R2 + R3 = 14-24 requirement. Therefore, the examiner disagrees that the "wherein" clause must be interpreted as a requirement, but instead maintains that the "wherein" clause of Romano is a preferred embodiment, not a requirement.

Applicant argues that when the disclosure is read as a whole as is required by MPEP 2141.02, the "wherein" clause would have to be interepreted as a requirement. The examiner agrees that the reference as a whole must be carefully considered. However, as set forth above, since some of the preferred embodiments of Romano fall outside of the requirements of 14-24 carbon atoms and an exemplified compound also falls outside the requirements of 14-24 carbon atoms, the disclosure as a whole has been considered and the position of the examiner is that the "wherein" clause denotes a preferred embodiment and not a requirement.

Applicant argues that even if Romano did not mandate that the sum of R1 + R2 + R3 = 14-24, Romano does not disclose glycine betaine because it discloses many options and the preferred examples clearly teach away from glycine betaine. However, Romano discloses that betaines are useful as surfactants. The particularly claimed betaine has each of R1, R2 and R3 being an alkyl group comprising one carbon atom, i.e., a methyl group. Therefore, a person

Application/Control Number: 10/029,322

Art Unit: 1771

skilled in the art would have immediately recognized glycine betaine from the disclosure in Romano.

With regard to the combination of Mandell and Romano with Lorenzi, Applicant argues that Lorenzi does not disclose the claimed betaine compounds. However, Lorenzi was not relied upon for teaching the claimed betaine compounds, but for the teaching regarding the benefits of incorporating liposomes into personal care articles.

8. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth M. Cole whose telephone number is (571) 272-1475. The examiner may be reached between 6:30 AM and 6:00 PM Monday through Wednesday, and 6:30 AM and 2 PM on Thursday.

Mr. Terrel Morris, the examiner's supervisor, may be reached at (571) 272-1478.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

Art Unit: 1771

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The fax number for all official faxes is (703) 872-9306.

Elizabeth M. Cole Primary Examiner Art Unit 1771

e.m.c